Headlines about GTx (NASDAQ:GTXI) have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. GTx earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.5208475360316 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern’s scoring:
- GTx (GTXI) vs. Its Peers Financial Comparison (americanbankingnews.com)
- Comparing GTx (GTXI) and Its Peers (americanbankingnews.com)
- Top 7 Shares Gapping Up this Morning – ALDX, FINL, CNC, SNAK, FRTA, GTXI, MHH (fxpips.com)
- GTx, Inc. (GTXI) Reports ositive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with SUI (streetinsider.com)
- GTx’s (GTXI) Enobosarm Positive in Phase II, Shares Down (finance.yahoo.com)
Shares of GTx (NASDAQ:GTXI) traded up 3.73% on Tuesday, hitting $8.34. The stock had a trading volume of 4,371 shares. GTx has a 52 week low of $0.65 and a 52 week high of $9.71. The company’s market capitalization is $133.92 million. The company has a 50-day moving average of $6.36 and a 200 day moving average of $5.15.
GTx (NASDAQ:GTXI) last issued its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.40) EPS for the quarter. On average, equities research analysts predict that GTx will post ($1.16) EPS for the current year.
Separately, ValuEngine upgraded GTx from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 13th.
GTx Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.